Skip to main content
. Author manuscript; available in PMC: 2021 Aug 6.
Published in final edited form as: J Am Coll Cardiol. 2019 Mar 17;74(10):1376–1414. doi: 10.1016/j.jacc.2019.03.009

Recommendations for Assessment of Cardiovascular Risk

Referenced studies that support recommendations are summarized in Online Data Supplement 3.

COR LOE RECOMMENDATIONS
I B-NR 1. For adults 40 to 75 years of age, clinicians should routinely assess traditional cardiovascular risk factors and calculate 10-year risk of ASCVD by using the pooled cohort equations (PCE) (S2.2-1,S2.2-2).
IIa B-NR 2. For adults 20 to 39 years of age, it is reasonable to assess traditional ASCVD risk factors at least every 4 to 6 years (S2.2-1S2.2-3).
IIa B-NR 3. In adults at borderline risk (5% to <7.5% 10-year ASCVD risk) or intermediate risk (≥7.5% to <20% 10-year ASCVD risk), it is reasonable to use additional risk-enhancing factors to guide decisions about preventive interventions (e.g., statin therapy) (S2.2-4S2.2-14).
IIa B-NR 4. In adults at intermediate risk (≥7.5% to <20% 10-year ASCVD risk) or selected adults at borderline risk (5% to <7.5% 10-year ASCVD risk), if risk-based decisions for preventive interventions (e.g., statin therapy) remain uncertain, it is reasonable to measure a coronary artery calcium score to guide clinician–patient risk discussion (S2.2-15S2.2-31).
IIb B-NR 5. For adults 20 to 39 years of age and for those 40 to 59 years of age who have <7.5% 10-year ASCVD risk, estimating lifetime or 30-year ASCVD risk may be considered (S2.2-1,S2.2-2,S2.2-32S2.2-35).